📊 BMEZ Key Takeaways
Is BlackRock Health Sciences Term Trust (BMEZ) a Good Investment?
BlackRock Health Sciences Term Trust (BMEZ) is a closed-end fund with insufficient fundamental data available for meaningful analysis. With only 1 metric available and no income statement, balance sheet, or cash flow data, a comprehensive assessment of financial health and performance is impossible. The minimal data quality severely limits the ability to evaluate investment merit based on fundamentals.
BMEZ's 2025 SEC filings show a clear rebound in core portfolio performance, with net assets benefiting from $58.8 million of realized gains and $45.4 million of unrealized appreciation after a much weaker 2024. Financial health is solid because liabilities are minimal relative to assets and there is no meaningful balance-sheet debt, but the fund's distribution quality remains weak given negative net investment income and heavy reliance on return of capital.
Why Buy BlackRock Health Sciences Term Trust Stock? BMEZ Key Strengths
- Closed-end fund structure with defined management team (implied by BlackRock branding)
- Recent insider activity indicating management engagement (3 Form 4 filings in 90 days)
- Focus on healthcare/life sciences sector provides thematic diversification
- 2025 net increase in net assets from operations improved to about $99.9 million versus $23.7 million in 2024
- Balance sheet is strong with roughly $1.08 billion of assets against only about $8.3 million of liabilities and no meaningful leverage
- Net asset value per share rose from $16.43 to $17.10 in 2025, reflecting materially better portfolio execution
BMEZ Stock Risks: BlackRock Health Sciences Term Trust Investment Risks
- Acute lack of financial data - 99% of metrics unavailable for analysis
- Unable to assess fund performance, holdings quality, or distribution sustainability
- No visibility into net asset value, expense ratios, leverage, or portfolio composition
- Cannot evaluate profitability or financial health of underlying portfolio
- Net investment income turned negative at about negative $4.2 million in 2025, indicating weak income coverage
- Distributions relied heavily on return of capital, about $120.0 million in 2025, which can pressure long-term capital if performance softens
- Level 3 assets were about $143.9 million at year-end, creating valuation uncertainty and liquidity risk in stressed markets
Key Metrics to Watch
- Net Asset Value (NAV) and NAV per share trends
- Fund distribution rate and payout sustainability
- Portfolio composition and concentration in healthcare securities
- Net investment income versus total distributions, especially the share funded by return of capital
- Net asset value trend and the size of Level 3/private holdings as a percentage of net assets
BlackRock Health Sciences Term Trust (BMEZ) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
BMEZ Profit Margin, ROE & Profitability Analysis
BMEZ vs Market Sector: How BlackRock Health Sciences Term Trust Compares
How BlackRock Health Sciences Term Trust compares to Market sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is BlackRock Health Sciences Term Trust Stock Overvalued? BMEZ Valuation Analysis 2026
Based on fundamental analysis, BlackRock Health Sciences Term Trust has mixed fundamental signals relative to the Market sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
BlackRock Health Sciences Term Trust Balance Sheet: BMEZ Debt, Cash & Liquidity
BMEZ Revenue Growth, EPS Growth & YoY Performance
BMEZ SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for BlackRock Health Sciences Term Trust (CIK: 0001785971)
📋 Recent SEC Filings
❓ Frequently Asked Questions about BMEZ
What is the AI rating for BMEZ?
BlackRock Health Sciences Term Trust (BMEZ) has a Combined AI Rating of HOLD from Claude (HOLD) and ChatGPT (HOLD) with 44% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are BMEZ's key strengths?
Claude: Closed-end fund structure with defined management team (implied by BlackRock branding). Recent insider activity indicating management engagement (3 Form 4 filings in 90 days). ChatGPT: 2025 net increase in net assets from operations improved to about $99.9 million versus $23.7 million in 2024. Balance sheet is strong with roughly $1.08 billion of assets against only about $8.3 million of liabilities and no meaningful leverage.
What are the risks of investing in BMEZ?
Claude: Acute lack of financial data - 99% of metrics unavailable for analysis. Unable to assess fund performance, holdings quality, or distribution sustainability. ChatGPT: Net investment income turned negative at about negative $4.2 million in 2025, indicating weak income coverage. Distributions relied heavily on return of capital, about $120.0 million in 2025, which can pressure long-term capital if performance softens.
What is BMEZ's revenue and growth?
BlackRock Health Sciences Term Trust reported revenue of N/A.
Does BMEZ pay dividends?
BlackRock Health Sciences Term Trust does not currently pay dividends.
Where can I find BMEZ SEC filings?
Official SEC filings for BlackRock Health Sciences Term Trust (CIK: 0001785971) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is BMEZ's EPS?
BlackRock Health Sciences Term Trust has a diluted EPS of $0.00.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is BMEZ a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, BlackRock Health Sciences Term Trust has a HOLD rating with 44% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is BMEZ stock overvalued or undervalued?
Valuation metrics for BMEZ: ROE of N/A (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy BMEZ stock in 2026?
Our dual AI analysis gives BlackRock Health Sciences Term Trust a combined HOLD rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is BMEZ's free cash flow?
BlackRock Health Sciences Term Trust's operating cash flow is N/A, with capital expenditures of N/A.
How does BMEZ compare to other Market stocks?
Vs Default sector averages: Net margin N/A (avg: 12%), ROE N/A (avg: 15%), current ratio N/A (avg: 1.8).